Bioluminescence imaging of Hepatitis C virus NS3/4A serine protease activity in cells and living animals

被引:22
作者
Wang, Licui [1 ]
Fu, Qiuxia [1 ]
Dong, Yafeng [1 ]
Zhou, Yong [1 ]
Jia, Shuaizheng [1 ]
Du, Juan [1 ]
Zhao, Fang [1 ]
Wang, Yingli [1 ]
Wang, Xiaohui [1 ]
Peng, Jianchun [1 ]
Yang, Shuhua [1 ]
Zhan, Linsheng [1 ]
机构
[1] Beijing Inst Transfus Med, Lab Blood Borne Virus, Beijing 100850, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
NS3/4A protease; Split firefly luciferase complementation strategy; In vivo imaging; RNA REPLICATION; IN-VIVO; INFECTION; CULTURE; ASSAY; INTERFERENCE; REPLICON; VIREMIA; LINES;
D O I
10.1016/j.antiviral.2010.04.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The lack of robust small animal models has been an obstacle to the screening of Hepatitis C virus (HCV) NS3/4A protease inhibitors in vivo. Here, we described a reporter assay system for in vivo noninvasive imaging of NS3/4A serine protease activity using split firefly luciferase complementation strategy. The reporter construct ANIuc(NS5A/B)BCluc constitutes the split N- and C-terminal fragments of luciferase, fused to interacting peptides, pepA and pepB, respectively, with an intervening HCV NS3/4A cleavage motif of NSSA/B. we proved that the reporter molecule could be proteolytically cleaved by NS3/4A at the NS5A/B motif in cells and living animals. Association of pepA and pepB brought inactive fragments of luciferase into close proximity, thereby restoring bioluminescence activity. The increase in luciferase activity was proportional to the dose of active NS3/4A protease. The ANIuc(NS5A/B)BCluc reporter also could be used to detect the activity of NS3/4A-specific shRNA and IFN-alpha. Therefore, the reporter assay system using split firefly luciferase complementation strategy should prove useful for evaluating NS3/4A protease activity in cells and living animals. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [21] Portulaca oleracea L. as a Prospective Candidate Inhibitor of Hepatitis C Virus NS3 Serine Protease
    Noreen, Sobia
    Hussain, Ishtiaq
    Tariq, Muhammad Ilyas
    Ijaz, Bushra
    Iqbal, Shahid
    Qamar-ul-Zaman
    Ashfaq, Usman Ali
    Husnain, Tayyab
    VIRAL IMMUNOLOGY, 2015, 28 (05) : 282 - 289
  • [22] Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
    McPhee, Fiona
    Friborg, Jacques
    Levine, Steven
    Chen, Chaoqun
    Falk, Paul
    Yu, Fei
    Hernandez, Dennis
    Lee, Min S.
    Chaniewski, Susan
    Sheaffer, Amy K.
    Pasquinelli, Claudio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3670 - 3681
  • [23] Establishment of a novel triple-transgenic mouse: conditionally and liver-specifically expressing hepatitis C virus NS3/4A protease
    Lan, H. Y.
    Zhao, Y.
    Yang, J.
    Sun, M. N.
    Lei, Y. F.
    Yao, M.
    Huang, X. J.
    Zhang, J. M.
    Xu, Z. K.
    Lu, X.
    Yin, W.
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (11) : 7349 - 7359
  • [24] Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®
    Taylor, James G.
    Zipfel, Sheila
    Ramey, Kyla
    Vivian, Randy
    Schrier, Adam
    Karki, Kapil K.
    Katana, Ashley
    Kato, Darryl
    Kobayashi, Tetsuya
    Martinez, Ruben
    Sangi, Michael
    Siegel, Dustin
    Tran, Chinh, V
    Yang, Zheng-Yu
    Zablocki, Jeff
    Yang, Cheng Y.
    Wang, Yujin
    Wang, Kelly
    Chan, Katie
    Barauskas, Ona
    Cheng, Guofeng
    Jin, Debi
    Schultze, Brian E.
    Appleby, Todd
    Villasenor, Armando G.
    Link, John O.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (16) : 2428 - 2436
  • [25] Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C
    Klibanov, Olga M.
    Williams, Shannon H.
    Smith, Lisa S.
    Olin, Jacqueline L.
    Vickery, Stephen B.
    PHARMACOTHERAPY, 2011, 31 (10): : 951 - 974
  • [26] GRAZOPREVIR POTASSIUM HCV NS3 NS4A protease inhibitor Anti-hepatitis C virus drug
    Majumdar, A.
    Gilliam, B. L.
    DRUGS OF THE FUTURE, 2016, 41 (02) : 85 - 109
  • [27] Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
    Soumana, Djade I.
    Ali, Akbar
    Schiffer, Celia A.
    ACS CHEMICAL BIOLOGY, 2014, 9 (11) : 2485 - 2490
  • [28] Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants
    Matthew, Ashley N.
    Zephyr, Jacqueto
    Hill, Caitlin. J.
    Jahangir, Muhammad
    Newton, Alicia
    Petropoulos, Christos J.
    Huang, Wei
    Kurt-Yilmaz, Nese
    Schiffer, Celia A.
    Ali, Akbar
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) : 5699 - 5716
  • [29] Treatment of HCV infection with the novel NS3/4A protease inhibitors
    De Luca, Andrea
    Bianco, Claudia
    Rossetti, Barbara
    CURRENT OPINION IN PHARMACOLOGY, 2014, 18 : 9 - 17
  • [30] A magnetic microparticle-based immunoassay for hepatitis C virus NS3 antigen
    Xie, Li
    Guang, Yue-ping
    Liu, Fang
    Shi, Hong-bo
    Yan, Li
    Lou, Jin-li
    AFRICAN JOURNAL OF MICROBIOLOGY RESEARCH, 2011, 5 (01): : 28 - 33